newsfilter
← Latest News
GlobeNewswire·

Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025

Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock SCAI Stage C Cardiogenic shock SCAI Stage C has an in hospital mortality rate of 20-30% Istaroxime interim